Vicore Pharma gets regulatory approval to start phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection
Gothenburg, April 28, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces the approval by the UK regulatory agency (MHRA[1]) of the clinical trial application (CTA) for a phase II study with the proprietary compound VP01 (C21) in patients with COVID-19, SARS CoV-2 infection.Only four weeks after submitting a Letter of Intent to file a CTA to start the process, Vicore Pharma has completed the submission and gained approval from the agency to start the study. The study, named ATTRACT (